Ganglioneuroblastomas most commonly occur
in infants and young children and almost never occur after age
10 years. Ganglioneuroblastoma and neuroblastoma tend to occur in
young children with the median age of 2 years.
Ganglioneuroblastomas are a mix of malignant neuroblastoma and
benign ganglioneuroma, and they are sometimes called transitional
tumors. These lesions also originate from sympathetic cells.
Histologically, they are considered malignant because they contain
primitive neuroblasts along with mature ganglion cells.
Ganglioneuroblastomas have a propensity for secreting
catecholamines, and approximately 90-95% actively secrete
vanillylmandelic acid (VMA) and homovanillic acid (HVA). HVA tends to
be secreted by more mature and differentiated tumors, and VMA is
usually a product of less differentiated tumors. In fact, the ratio
of VMA to HVA can be used to assess tumor maturity, thereby being a
prognostic factor. In addition, more mature tumors may contain
vasoactive intestinal peptide (VIP) producing ganglion cells.
Despite these possible comorbidities, the prognosis for patients
with a ganglioneuroblastoma is still relatively good. These tumors
can spontaneously regress or mature. In fact,
all ganglioneuromas are thought to have once been
ganglioneuroblastomas/neuroblastomas at an earlier stage of their
development. Regression has an unknown cause and
occurs in 1-2% of tumors.
Patients with
ganglioneuroblastomas often present with pain caused by either the
primary tumor or metastatic disease and abdominal distention.
Patients may also complain of irritability, weight loss, malaise,
shortness of breath, peripheral neurologic symptoms (nerve or nerve
root compression), and Horner syndrome (ptosis, myosis, and
ipsilateral anhydrosis).